These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Sacituzumab tirumotecan showed “promising efficacy” regardless of PD-L1 status, said study presenter Yongmei Yin, MD, PhD.

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

An expert discusses the evolving role of biomarker testing in first-line metastatic triple-negative breast cancer (mTNBC), ...

Gilead is continuing to explore sacituzumab govitecan in other phase 3 trials, including ASCENT-07 (ClinicalTrials.gov Identifier: NCT05840211) for hormone receptor–positive, human epidermal ...

Women with metastatic triple-negative breast cancer benefited from sacituzumab govitecan irrespective of their Trop-2 expression level and BRCA1/BRCA2 mutation status, according to data from the ...

CHICAGO -- Treatment with single-agent sacituzumab govitecan (Trodelvy) offered no survival advantage over docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated ...

Sacituzumab govitecan continues to be developed for potential use in other TNBC and metastatic UC populations and is also being developed as an investigational treatment for hormone receptor ...

Sacituzumab govitecan (Trodelvy) beat chemotherapy in patients with heavily pretreated endocrine resistant HR+/HER2- advanced breast cancer, who represent a 'great clinical unmet need,' says expert.

Sacituzumab Govitecan Boosts PFS in Late-Line HR+/HER2- Metastatic Breast Cancer — "This may be something that really changes the lives of these women for the better," expert says.

Sacituzumab govitecan, a Trop-2-directed antibody and topoisomerase inhibitor conjugate, binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38, ...

3.2 The marketing authorisation for sacituzumab govitecan specifies its use after 2 or more prior systemic therapies, 1 of which should have been for advanced disease. For people who have ...